Retinopathy a mild concern in semaglutide briefing docs

In briefing documents issued ahead of an advisory committee meeting for subcutaneous semaglutide (NN9353) from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO), FDA reviewers acknowledged that the candidate poses a risk of diabetic retinopathy, but noted that ophthalmology experts believe the program "does not raise any ophthalmic concerns." FDA's Endocrinologic and Metabolic Drugs Advisory Committee is to meet Wednesday to discuss an NDA for semaglutide as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes.

On Monday, Novo gained DKK14.90 to DKK312.70 in Copenhagen and $1.79 to $49.32 in New York...